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Abstract
Nitric oxide (NO) seems to contribute to vascular homeostasis regulating neurotransmis-
sion. This work aimed at assessing the influence of NO from different sources and re-
spective intracellular pathways on sympathetic neurotransmission, in two vascular beds.
Electrically-evoked [3H]-noradrenaline release was assessed in rat mesenteric and tail ar-
teries in the presence of NO donors or endothelial/neuronal nitric oxide synthase (NOS)
inhibitors. The influence of NO on adenosine-mediated effects was also studied using se-
lective antagonists for adenosine receptors subtypes. Location of neuronal NOS (nNOS)
was investigated by immunohistochemistry (with specific antibodies for nNOS and for
Schwann cells) and Confocal Microscopy. Results indicated that: 1) in mesenteric arteries,
noradrenaline release was reduced by NO donors and it was increased by nNOS inhibitors;
the effect of NO donors was only abolished by the adenosine A1 receptors antagonist; 2)
in tail arteries, noradrenaline release was increased by NO donors and it was reduced by
eNOS inhibitors; adenosine receptors antagonists were devoid of effect; 3) confocal micros-
copy showed nNOS staining in adventitial cells, some co-localized with Schwann cells.
nNOS staining and its co-localization with Schwann cells were significantly lower in tail com-
pared to mesenteric arteries. In conclusion, in mesenteric arteries, nNOS, mainly located in
Schwann cells, seems to be the main source of NO influencing perivascular sympathetic
neurotransmission with an inhibitory effect, mediated by adenosine A1 receptors activation.
Instead, in tail arteries endothelial NO seems to play a more relevant role and has a facilita-
tory effect, independent of adenosine receptors activation.
PLOS ONE | DOI:10.1371/journal.pone.0129224 June 15, 2015 1 / 15
OPEN ACCESS
Citation: Sousa JB, Vieira-Rocha MS, Arribas SM,
González MC, Fresco P, Diniz C (2015) Endothelial
and Neuronal Nitric Oxide Activate Distinct Pathways
on Sympathetic Neurotransmission in Rat Tail and
Mesenteric Arteries. PLoS ONE 10(6): e0129224.
doi:10.1371/journal.pone.0129224
Academic Editor: Alexander A. Mongin, Albany
Medical College, UNITED STATES
Received: March 5, 2015
Accepted: May 6, 2015
Published: June 15, 2015
Copyright: © 2015 Sousa et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was supported by FEDER
through Program of Operational Competitiveness
Factors - COMPETE and by National Funds through
Foundation for Science and Technology (FCT): Grant
N°. PEst C/EQB/LA0006/2011. JBS was supported
by PhD grant (SFRH/BD//2009) - FCT (URL: http://
www.fct.pt/). The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Introduction
Nitric oxide (NO) contributes to vascular homeostasis [1–3] by modulating the vascular dilator
tone and regulating local cell growth. Since NO is an uncharged and highly soluble molecule in
hydrophobic environments, it can freely diffuse across biological membranes and signal on vas-
cular cells distant from its site of generation [4]. Therefore, NO can modify vascular smooth
muscle tone directly, acting on smooth muscle cells, or indirectly, by modulating sympathetic
neurotransmission. In fact, there is evidence demonstrating the influence of NO on sympathetic
neurotransmission in various vascular beds, such as mesenteric artery [5–12], pulmonary artery
[13–15], heart and coronary arteries [12,16]. There are conflicting data concerning the influence
exerted by NO on noradrenaline release: some authors claim that NO inhibits [17,18] whereas
other studies showed an increase in noradrenaline release caused by NO [19–21]. However, most
of these studies have been performed in heart, brain or urethra and, therefore, information on
the direct influence of NO on perivascular sympathetic transmission is not fully understood.
It is conceivable that NO mediated-effects, in addition to the classically accepted activation
of intracellular cGMP-dependent pathways [19] can also be related to cGMP-independent
pathways, namely by inducing a decrease in mitochondrial respiration, with subsequent adeno-
sine accumulation [22]. Therefore, it is possible that adenosine and its receptors (adenosine re-
ceptors) might participate on the modulation of sympathetic neurotransmission exerted by
NO. It is worth noting that we have previously demonstrated that adenosine receptors are pres-
ent in perivascular sympathetic nerves modulating noradrenaline release in mesenteric [23–25]
and tail arteries [26–30].
This work aimed to clarify the NO influence on perivascular sympathetic neurotransmission
(noradrenaline release), assessing: 1) the source of vascular NO, 2) the intracellular pathways
implicated and 3) the potential role of adenosine or its receptors. For this purpose, in the pres-
ent study, two different vessels were used, mesenteric and tail arteries, which have been exten-
sively used as models for the study of neuromodulation exerted by many substances in the
vasculature [5,7,8,31–33] and where we have previously described the presence of adenosine
receptors on sympathetic nerves [24,27].
Materials and Methods
Handling and care of animals were conducted according to the European guidelines (Directive
2010/63/EU) on the protection of animals used for scientific purposes in agreement with the
NIH guidelines. This study was carried out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal Experiments of the Universi-
ty of Porto (Permit Number: 13/11/2013).
Animals and arterial tissue
Adult male Wistar Kyoto rats (12 weeks old, 270–350 g; Charles River, Barcelona, Spain) were
used. Animals were sacrificed using guillotine. Seven arterial segments (5 to 9 mg) were ob-
tained from each tail artery and four arterial segments (4–7 mg) were obtained from each
mesenteric artery. Two animals per experiment were used. For each condition, results obtained
from 5 to 24 tissue segments were analyzed.
Chemicals
The following drugs were used: levo-[ring-2,5,6-3H]-noradrenaline, specific activity 41.3 Ci/
mmol, was from DuPont NEN (I.L.C., Lisboa, Portugal); Desipramine hydrochloride, Sodium
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Nitroprusside (SNP), DiethylamineNONOate diethylammonium salt (DEA-NONOate), Nω-
Nitro-L-arginine methyl ester hydrochloride (L-NAME), Nω-Propyl-L-arginine hydrochloride
and L-NIO dihydrochloride, desipramine hydrochloride, 8-cyclopentyl-1,3-dipropylxanthine
(DPCPX), 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c] py-
rimidine (SCH 58261), 5-Iodotubericidin (ITU) and Triton X-100 were purchased from
Sigma-Aldrich (Sintra, Portugal). The following antibodies were used: mouse monoclonal anti-
NOS1 (sc-5302),were purchased from Santa Cruz Biotechnology, Inc., CA, USA; rabbit GFAP
polyclonal antibody (18–0063) was purchased from Invitrogen, Life Technologies, SA, Madrid,
Spain). The following fluorescent probes were used: Alexa Fluor 488 goat anti-mouse IgG (H
+L) antibody, highly cross-adsorbed and Alexa Fluor 647 goat anti-rabbit IgG (H+L) antibody,
highly cross-adsorbed (Molecular Probes) secondary fluorescent antibodies (Invitrogen, Life
Technologies, SA, Madrid, Spain); vectashield mounting medium with DAPI (Vector Labora-
tories, UK). Stock solutions were made up in dimethylsulphoxide (DMSO: 0.01% v/v, final con-
centration) or distilled water and diluted in superfusion medium immediately before use.
DMSO was added to the superfusion medium (final concentration 0.01%), in parallel control
experiments.
[3H]-Noradrenaline release experiments
[3H]-noradrenaline release experiments were carried out as previously described [23,24,27–
29]. Briefly, the arterial segments were pre-incubated in 2 ml Krebs-Henseleit solution contain-
ing 0.1 μmol/L [3H]- noradrenaline (for 60 min at 37°C) and transferred to superfusion cham-
bers, superfused with [3H]-noradrenaline-free medium (1 ml.min-1; constant rate: Krebs-
Henseleit solution with desipramine 400 nmol/L to inhibit noradrenaline’s neuronal uptake).
Up to three periods of electrical stimulation (5 Hz, 100 pulses, 1 ms, 50 mA; Hugo Sachs Elek-
tronik, March-Hugstetten, Germany): two stimulation periods (S1 and S2) were applied with
30 min intervals, t = 90 min and t = 120 min, respectively. The superfusate was collected each 5
min period from 85 min of superfusion onwards. At the end of the experiments (t = 130 min),
tritium was measured in superfusate samples and solubilized arteries (sonicated for 1h with 2.5
ml perchloric acid (0.2 mol/L)) by liquid scintillation spectrometry (LS 6500, Beckman Instru-
ments, Fullerton, USA) after adding 6 ml of a scintillation mixture (OptiPhase ‘Hisafe’ 3, Perki-
nElmer, I.L.C., Lisboa, Portugal) to each sample. Tissue labelling with [3H]-noradrenaline and
evaluation of electrically-evoked tritium overflow changes was performed as previously de-
scribed [23,24].
To study the effects of NO from different sources, experiments were performed in the pres-
ence or absence of NOS inhibitors (Nω-Nitro-L-arginine methyl ester hydrochloride, Nω-Pro-
pyl-L-arginine hydrochloride and L-NIO dihydrochloride) and donors (SNP and
DEA-NONOate), adenosine receptors antagonists (DPCPX and SCH 58621) or the adenosine
kinase inhibitor (ITU), which were added after S1 and kept until the end of the experiment.
Laser scanning confocal microscopy (LSCM) experiments
Immunohistochemistry procedures were performed as previously described [24]. From each
artery four segments were obtained, immediately placed in cold phosphate buffer solution
(PBS; in g/L): NaCl 8.0, Na2HPO4.2H2O 0.77, KCl 0.20, KH2PO4 0.19 (pH 7.2), longitudinally
opened and fixed (paraformaldehyde 4% in PBS; 50 min; room temperature, RT). After two 15
min washing cycles with PBS-T (PBS with 0.3% of Triton X-100), each arterial segment was in-
cubated with the primary antibodies against: nNOS, (mouse monoclonal anti-NOS1; 1:200 di-
lution, overnight, 4°C) and GFAP (rabbit polyclonal anti-glial fibrillary acidic protein, 1:200
dilution, overnight, 4°C). After a PBS (4x15min) washout period, tissues were incubated with
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Alexa 488 anti-mouse and Alexa 647 anti-rabbit fluorescent secondary antibodies (1:1000 dilu-
tion, 1h, RT). Negative controls were performed by omitting primary antibodies. After two
PBS washing cycles, tissue preparations were mounted with antifading agent (vectashield
mounting medium with DAPI, Vector Laboratories, UK), with the adventitial side facing up.
Preparations were visualized with a Leica SP5 laser scanning confocal microscopy system
(Leica Microsystems, Germany) fitted with an inverted microscope (x63 oil immersion lens).
Stacks of 1-μm-thick serial optical images were captured from the entire adventitial layer,
which was identified by the shape and orientation of the nuclei. Image acquisition was per-
formed always under the same laser power, brightness and contrast conditions. Serial images
from 3 different regions of the adventitia layer were acquired from each mesenteric and tail ar-
tery at 360 nm Ex/ 460 nm Em (for location of cell nuclei), at 488 nm Ex/525 nm Em (location
of nNOS containing cells) and at 633 nm Ex/665 nm Em (location of Schwann cells) wave-
lengths. The resulting images were reconstructed separately for each wavelength with the Leica
SP5 laser scanning confocal microscopy system (Leica Microsystems, Germany).
Data Analysis
Measurement of drug effects on electrically-evoked tritium overflow. Electrically-
evoked tritium overflow from artery segments incubated with [3H]-noradrenaline has been
shown to reflect action potential-evoked neuronal noradrenaline release and drug-induced
changes in evoked tritium overflow are assumed to reflect changes in neuronal noradrenaline
release. Effects of drugs added after S1 on electrically-evoked tritium overflow were evaluated
as ratios of the overflow elicited by S2 and the overflow elicited by S1 (S2/S1). S2/S1 ratios ob-
tained in individual experiments in which a test compound A was added after S1 were calculat-
ed as a percentage of the respective mean ratio in the appropriate control group (solvent
instead of A) [25–27,34–36].
Laser Scanning Confocal Microscopy image quantification. Quantitative analysis of
confocal z-stacks images was performed using an image analysis software (PAQI, CEMUP,
OPorto, Portugal). Briefly, a sequential routine was designed and developed to analyze each
fluorescent signal used. PAQI software measured the surface area and intensity of immunoflu-
orescence of the antibody against neuronal NOS isoform, the surface area and intensity of
immunofluorescence of the antibody against GFAP and determined the surface area of attach-
ment of the antibodies anti-nNOS and anti-GFAP.
Statistics. Results are expressed as mean±s.e.m. and n denotes the number of animals used
with triplicate tissue preparations. Differences of means were compared for significance using
one-way ANOVA and the post-hocHolm-Sidak’s multicomparisons test. A P value lower than
0.05, 0.01 or 0.001 was considered to denote statistically significant differences.
Results
The fractional rate of basal tritium outflow (b1), electrically-evoked tritium overflow (S1) and
S2/S1 ratios of mesenteric and tail arteries are shown in Table 1 and Fig 1.
Basal outflow and electrically-evoked tritium overflow remained constant throughout the
control experiments, with bn/b1 and Sn/S1 values close to unity. Electrically-evoked tritium
overflow (S1) was similar in mesenteric and tail arteries. However, in the presence of NO do-
nors, DEA-NONOate (10 μM) or SNP (10 μM), opposite effects in the S2 electrically-evoked
tritium overflow were observed: in mesenteric arteries, NO donors caused an inhibition where-
as in tail arteries these compounds induced facilitation, as depicted in Fig 1.
In the mesenteric artery, inhibition of electrically-evoked tritium overflow induced by DEA/
NONOate was abolished by the selective adenosine A1 receptors antagonist, DPCPX (20 nM),
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and was not altered by the selective adenosine A2A receptors antagonist, SCH 58261 (20 nM),
or by the adenosine kinase inhibitor, ITU (100 nM; Fig 2). In the tail artery, however, neither
adenosine receptors antagonists (DPCPX and SCH 58261) nor the adenosine kinase inhibitor,
ITU, affected facilitation of electrically-evoked tritium overflow elicited by NO. Adenosine re-
ceptor antagonists did not influence tritium overflow as depicted in Table 2.
In mesenteric artery, L-NAME (a non-selective NOS inhibitor) and Nω-Propyl-L-arginine
hydrochloride (a selective nNOS inhibitor) facilitated electrically-evoked tritium overflow up
to 21% and 35%, respectively (Fig 3). However, L-NIO dihydrochloride, a selective eNOS in-
hibitor, was devoid of effect. In tail artery, however, the effect elicited by NOS inhibitors on the
electrically-evoked tritium overflow presented an opposite profile: L-NAME and L-NIO dihy-
drochloride inhibited electrically-evoked tritium overflow (in approximately 30%), an effect
compatible with the facilitatory role of NO donors described above in this artery, whereas the
nNOS inhibitor, failed to change tritium release (Fig 3).
Additional experiments were performed with endothelium removal (endothelium was me-
chanically removed from arteries with a stainless steel wire) in order to confirm the existence
of the two NO sources: endothelial or neuronal. In fact, endothelium removal in tail artery re-
verted L-NAME and L-NIO dihydrochloride mediated effects on the electrically-evoked triti-
um overflow (S2/S1, % of appropriate control, were 97,16% ± 8,33; n = 6 and 109,56% ± 13,03;
n = 5, for L-NAME and L-NIO dihydrochloride, respectively). Moreover, for mesenteric artery,
endothelium removal did not modified L-NAMEmediated effects when compared with results
obtained in intact arteries (S2/S1, % of appropriate control, was 117,51% ± 2,67; n = 4, for
L-NAME). Taking into consideration that L-NAME is a non-specific NOS inhibitor and have
the ability to inhibit both endothelial and neuronal NOS and, since L-NAME data, in denuded
and intact arteries, present the same effect on electrically-evoked tritium overflow, the putative
involvement of endothelial NO in altering neurotransmission can be discarded.
Results indicate distinct NOmodulatory roles in the two vessels in study which can be relat-
ed with differences in the NO source. To confirm this later possibility, the immunoreactivity
for nNOS, in the mesenteric and tail arteries, was studied (Fig 4A). We focused our attention to
Table 1. Basal tritium outflow (b1), electrically evoked tritium overflow (S1) and S2/S1 ratios frommesenteric and tail arteries.
Basal Outﬂow (b1) (fractional rate of outﬂow;
min-1)





Solvent 0.070±0.008 0.229±0.037 0.9801±0.048 6
DEA-NONOate 0.068±0.008 0.227±0.037 0.8082±0.063 * 4
Tail artery
Solvent 0.077±0.003 0.185±0.015 1.0275±0.081 6
DEA-NONOate 0.075±0.009 0.193±0.015 1.2665±0.067 * 4
Tissue preparations of mesenteric and caudal arteries were pre-incubated with [3H]-noradrenaline for 40 min. After pre-incubation with [3H]-noradrenaline,
tissues were superfused with [3H]-noradrenaline free medium containing desipramine (400 nM). Tissues were stimulated twice at 30-min intervals (S1-S2;
100 pulses, 5 Hz, 1 ms, 50 mA): b1 refers to the 5-min period immediately before S1. The electrically-evoked tritium overﬂow was calculated by subtracting
the estimated basal outﬂow from total outﬂow observed during and in the 25-min period subsequent to S1 and expressed as a percentage of the tissue
tritium content at the onset of stimulation. Values presented are means±SEM and n denotes the number of tissue preparations. Means were compared for
signiﬁcance using one-way ANOVA, followed by post-hoc Holm-Sidak´s multicomparisons t-test. Signiﬁcant differences from the respective solvent:
*P<0.050.
doi:10.1371/journal.pone.0129224.t001
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Fig 1. Panel A: time course of fractional tritium release frommesenteric and tail artery controls (filled
circles) and frommesenteric and tail arteries with the NO donor, DEA-NONOate (open circles) taken
from a typical experiment. Each line represents the outflow of tritium from a single superfusion chamber.
After pre-incubation with [3H]-noradrenaline, tissues were superfused with [3H]-noradrenaline free medium
containing desipramine (400 nM). Drugs were added immediately after S1 and kept until the end of the
experiment. Tritium outflow (ordinates) is expressed as a percentage of the total radioactivity present in the
tissue at the beginning of the collection period and was measured in samples collected every 5 min. Artery
segments were stimulated twice (S1, S2) using 100 pulses /5Hz, 1 ms, 50 mA. Panel B: Influence of nitric
oxide donors, SNP (10μM) and DEA-NONOate (10μM), on the modulation of electrically evoked tritium
overflow in tail and mesenteric arteries. Arteries were electrically stimulated (S1-S2: 100 pulses, 5 Hz, 1 ms,
50 mA). Drugs were added immediately after S1 and kept until the end of the experiment.Ordinates: S2/S1
values obtained in individual tissue preparations, expressed as a percentage of the appropriate S2/S1 control
value. Values are mean±s.e.m. from n = 4–6. Significant differences from solvent: *P<0.05 (one-way ANOVA
followed by post-hocHolm-Sidak’s multicomparisons t-test).
doi:10.1371/journal.pone.0129224.g001
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he vascular adventitia layer since our goal was to analyse the vascular sympathetic neurotrans-
mission, an event that occurs in the sympathetic nerves spread in the adventitia layer. LSCM
images from the adventitial layers, of both mesenteric and tail arteries, exhibited nNOS isoform
immunoreactivities (Fig 4A), but quantitative analysis evidenced that the relative amount of
nNOS immunoreactivity present in tail arteries is lower (up to 27% lower) than that exhibited
in mesenteric arteries (Fig 4B). These results together with functional data (Fig 3) reveal and
support a differential role of nNOS in the tail and mesenteric arteries.
We have previously demonstrated that sympathetic nerves are surrounded by Schwann cells
(anti-GFAP-immunoreactivity) [25]. The putative presence of nNOS isoform in Schwann cells
was challenged. Data form LSCM images evidenced the occurrence of nNOS and GFAP over-
laid immunoreactivities (Fig 4A; depicted by filled arrows). Nevertheless, nNOS and GFAP
overlaid immunoreactivities are markedly lower in tail comparatively to mesenteric arteries
(after data normalization by total GFAP immunoreactivity): 50% of Schwann cells exhibit
nNOS immunoreactivity in mesenteric arteries versus 4% observed in tail arteries. Similar re-
sults were also observed in Fig 4D (upon normalization of nNOS-GFAP overlay with total
nNOS immunostaining). Indeed, nNOS and GFAP staining overlay might indicate that these
proteins can be located on the same cellular structure. Nonetheless, nNOS immunoreactivity
Fig 2. Influence of the adenosine kinase inhibitor (ITU), the adenosine A1 receptors antagonist
(DPCPX) and the adenosine A2A receptors antagonist (SCH 58261) in the nitric oxide donor
DEA-NONOate (10μM) inducedmodulation of electrically evoked tritium overflow, in mesenteric and
tail arteries. Arteries were electrically stimulated (S1-S2: 100 pulses, 5 Hz, 1 ms, 50 mA). Drugs were added
immediately after S1 and kept until the end of the experiment.Ordinates: S2/S1 values obtained in individual
tissue preparations, expressed as a percentage of the appropriate S2/S1 control value. Values are mean±s.e.
m. from n = 4–6. Significant differences from the appropriate control: *P<0.05; **P<0.01 and from
DEA-NONOate: #P<0.001 (one-way ANOVA followed by post-hoc Holm-Sidak’s multicomparisons t-test).
doi:10.1371/journal.pone.0129224.g002
Endothelial and Neuronal NO Influence on Sympathetic Neurotransmission
PLOS ONE | DOI:10.1371/journal.pone.0129224 June 15, 2015 7 / 15
was also observed in cells present in adventitia, other than Schwann cells, in both mesenteric
and tail artery images (depicted by open arrows): 62.5% in mesenteric and 88% in tail artery
images (Fig 4, A e D).
Taken together, these morphological data support the occurrence of differences on nNOS
isoform presence in mesenteric and tail arteries and reveal an important role for Schwann cells
as an NO source, in mesenteric arteries.
Discussion
The present results demonstrate that the NO modulatory role on sympathetic neurotransmis-
sion and the different contribution of NO from neuronal and endothelial sources are depen-
dent on the vascular bed. In mesenteric arteries nNOS, mainly localized in Schwann cells,
seems to be the main source of NO influencing perivascular sympathetic neurotransmission,
while in tail arteries the endothelium seems to play the most relevant role. Intracellular signal-
ling cascades and adenosine receptors involved in the two vessels are also different.
In mesenteric arteries we found that an increase in NO availability, via addition of NO do-
nors, reduced noradrenaline release in the synaptic cleft. As a consequence, a reduction in the
vasoconstrictor effect mediated by activation of smooth muscle α1-adrenoceptors will occur.
These results are in line with previous studies that reported an altered vascular reactivity in-
duced by NO at the sympathetic neuroeffector junction, ascribed to the deactivation of the va-
soconstrictor, noradrenaline in the rat mesenteric bed [37]. However, in tail arteries NO
mediated an opposite effect: an increase of noradrenaline release levels. Taken together, these
data seem to indicate a different neuromodulatory role of NO in the neurovascular junction of
mesenteric and tail arteries, most likely, due to the activation of different pathways.
In addition to the well characterized classical mechanism by which NO mediates its effects,
via sGC-cGMP-PKG [38–41], results obtained in the current study, suggest that, in mesenteric
arteries, inhibition of sympathetic transmission by NO seems to activate an alternative signal-
ing pathway and/or the involvement of different NOS isoforms. Increasing evidence suggest
that NO may also signal through a cGMP independent pathway: NO inhibits the Krebs cycle
Table 2. Adenosine receptors antagonists mediated tritium overflow frommesenteric and tail arteries
(S2/S1 ratios).
S2/S1 (% of solvent) n
Mesenteric artery
DPCPX 101.41 ± 2.67 4
SCH 58261 106.04 ± 3.08 8
Tail artery
DPCPX 99.46 ± 3.81 6
SCH 58261 98.70 ± 7.99 10
Tissue preparations of mesenteric and caudal arteries were pre-incubated with [3H]-noradrenaline for 40
min. After pre-incubation with [3H]-noradrenaline, tissues were superfused with [3H]-noradrenaline free
medium containing desipramine (400 nM). Tissues were stimulated twice at 30-min intervals (S1-S2; 100
pulses, 5 Hz, 1 ms, 50 mA). The electrically-evoked tritium overﬂow was calculated by subtracting the
estimated basal outﬂow from total outﬂow observed during and in the 25-min period subsequent to S1 and
expressed as a percentage of the tissue tritium content at the onset of stimulation. Values presented are
means ± SEM and n denotes the number of tissue preparations. Means were compared for signiﬁcance
using one-way ANOVA, followed by post-hoc Holm-Sidak´s multicomparisons t-test. No signiﬁcant
differences from the respective solvent were observed.
doi:10.1371/journal.pone.0129224.t002
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[42], and inhibits complex I and IV of the mitochondrial respiratory chain [43,44] compromis-
ing the mitochondrial function in neurons [45] leading to ATP hydrolysis and subsequent ac-
cumulation of adenosine [46,47] that, in turn, can signal through activation of high affinity
adenosine receptors (A1 and A2A subtypes) or low affinity adenosine receptors (A2B and A3
subtypes). Indeed, the inhibition of noradrenaline release induced by NO seems to be mediated
by activation (by adenosine) of the adenosine A1 receptors subtype since the inhibition of nor-
adrenaline release mediated by NO donors was prevented by the adenosine A1 receptors antag-
onist (DPCPX) but was not altered by the adenosine A2A receptors antagonist (SCH 58261).
Similar NO-mediated mechanisms have also been described to occur in several central nervous
system tissues, such as the hippocampus [48–50] or the nucleus tractus solitarius [51].
It is well established that adenosine availability in the extracellular space may depend on nu-
cleoside transporters and on the activity rate of adenosine kinase [52–54], as well as on the neu-
ronal exocytotic ATP release [55–57]. In mesenteric arteries, we have demonstrated previously
that exocytosis (induced by electrical field stimulation) did not modify the amount of adeno-
sine available at the extracellular space [25]. Therefore, adenosine accumulation in the present
Fig 3. Influence of nitric oxide inhibitors on the modulation of electrically- evoked tritium overflow in
tail and mesenteric arteries: interaction with nitric oxide inhibitors L-NAME (100 μM, a non-selective
nNOS inhibitor), Nω-Propyl-L-arginine hydrochloride (100 nM, a selective nNOS inhibitor) and L-NIO
dihydrochloride (500 nM, a selective eNOS inhibitor). Arteries were electrically stimulated (S1-S2: 100
pulses, 5 Hz, 1 ms, 50 mA). Drugs were added immediately after S1 and kept until the end of the experiment.
Ordinates: S2/S1 values obtained in individual tissue preparations, expressed as a percentage of the
appropriate S2/S1 control value. Values are mean±s.e.m. from n = 4–6. Significant differences from the
appropriate control: *P<0.05; **P<0.01; ***P<0.001 (one-way ANOVA followed by post-hoc Holm-Sidak’s
multicomparisons t-test).
doi:10.1371/journal.pone.0129224.g003
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conditions could result from the transport of adenosine via nucleoside transporters or from
adenosine kinase inhibition (adenosine kinase is inhibited by adenosine itself). The first hy-
pothesis was previously demonstrated by our group [25] whereas the later possibility was ruled
out in the present work, since ITU (an adenosine kinase inhibitor) was devoid of effect upon
the NO-induced (with NO donors) inhibition of noradrenaline release.
On the other hand, in mesenteric arteries, selective NOS isoform inhibitors also differential-
ly influenced noradrenaline release: nNOS inhibitors increased noradrenaline release, an effect
in agreement with results from previous studies in rat [7,9,10,37,58] and rabbit [59] which de-
scribed NO as a mediator able to reduce noradrenaline release. Instead, the eNOS inhibitor
showed no significant effect. Moreover, the non-selective NOS inhibitor, which inhibits both
isoforms (nNOS and eNOS), modified noradrenaline release in mesenteric arteries in a similar
Fig 4. nNOS in Schwann cells in the adventitia of tail and mesenteric arteries. (A) Representative
reconstructions of the adventitia from tail and mesenteric arteries. Images were captured with a confocal
microscope (Leica SP5 LSCM system fitted with an inverted microscope (x63 oil immersion lens). Stacks of
1μm-thick serial optical images were captured from the entire adventitial layer and reconstructed by software.
Arteries were stained for nNOS (a primary mouse monoclonal anti-NOS1 and a species specific secondary
Alexa 488 antibody: green), GFAP (a primary rabbit anti-GFAP polyclonal antibody and a species specific
secondary Alexa 647 antibody: magenta) and DAPI (nuclear stain, blue). Filled arrows evidence nNOS and
GFAP overlaid immunoreactivities; open arrows evidence nNOS immunoreactivities in cells other than
Schwann cells, present in adventitia. (B) Relative means of nNOS, GFAP and nNOS-GFAP overlay
expressed as percentage of mesenteric artery values. (C) Mean percentage of overlay rate with GFAP and
(D) mean percentage of overlay rate with nNOS are depicted. Values are mean±s.e.m. from n = 3–4.
Significant differences frommesenteric artery: *P<0.05. Scale bar = 20 μm.
doi:10.1371/journal.pone.0129224.g004
Endothelial and Neuronal NO Influence on Sympathetic Neurotransmission
PLOS ONE | DOI:10.1371/journal.pone.0129224 June 15, 2015 10 / 15
way to that observed for the nNOS inhibitor. These results suggest that, in mesenteric arteries,
only nNOS contributes to NO generation that, ultimately, will lead to the decrease in noradren-
aline release. NO generation can be ascribed two both oxygenase and reductase domains of NO
synthase. L-NAME, described to be unable to modify the activity of the reductase domain [60],
did not completely revert the endogenous NO mediated effects on noradrenaline release
whereas the nNOS inhibitor completely reverted it.
Similar experiments were carried out in the tail artery but, in this vessel, the NO-mediated
effects (increase of noradrenaline release) are due to NO generated only by the eNOS isoform.
The selective eNOS inhibitor and of the non-selective NOS inhibitor, caused a decrease in nor-
adrenaline release but the selective nNOS inhibitor failed to modify noradrenaline release in
tail arteries. Therefore, NO generated by eNOS isoform, in tail arteries, increases noradrenaline
release, as previously suggested to occur in mice kidneys, where the presynaptic active NO
seemed to be exclusively produced by the eNOS isoform [61].
It is accepted that NOS produces NO as result of the oxygenase and reductase domains ac-
tivities which are responsible for the conversion of L-arginine to L-citrulline plus NO and of
the conversion of nitrites to NO, respectively [62]. This later reaction was previously shown to
be not affected by L-NAME [60]. In tail artery, the inhibition promoted by eNOS inhibitors
(L-NAME and L-NIO dihydrochloride) completely reverted the effects mediated by NO on
sympathetic transmission (Fig 3). These results indicate that, in tail arteries, the major contri-
bution for NO production seems to be ascribed to the eNOS oxygenase domain.
In tail arteries, the enhancement of noradrenaline release (induced by NO) is, most likely,
due to the activation of signaling cascades different from those observed in mesenteric arteries.
In fact, data showed that the effects mediated by NO donors in sympathetic transmission were
not altered by the adenosine receptors antagonists studied (DPCPX and SCH 58261), nor the
adenosine kinase inhibitor, (ITU). These data do not support the occurrence of an adenosine
accumulation evoked by NO mediated effects on mitochondrial respiration [47], which are
known to require higher NO amounts [49]. This can be explained by a residual activity of the
eNOS reductase domain in tail arteries. Taken together, these data strongly suggests that this is
not the predominant pathway by which NO mediate its effects, in tail artery. Classically, it is
accepted that NO mediate its effects by activating guanylyl cyclase to generate cGMP. cGMP
and cGMP-dependent protein kinase are capable of modulating membrane potential and ion
channels [19,63]. Moreover, a cGMP-mediated enhancement of Ca2+ channel currents in sym-
pathetic neurons has also been reported [64]. It is, therefore, possible that the facilitation of
noradrenaline release induced by NO can be ascribed to cGMP-mediated changes in activated
voltage-dependent Ca2+ channels [19]. Moreover, data obtained in denuded arteries constitute
an additional support for hypothesis of the existence of distinct NO sources (confirmed by the
selective NOS inhibitors mediated effects) that will be responsible for activation of distinct
pathways on sympathetic neurotransmission in rat tail and mesenteric arteries.
Confocal microscopy studies showed the presence of nNOS isoform in the adventitia layer
of both mesenteric and tail arteries. These data agree well with those from a study that de-
scribed the presence of nNOS isoform in mesenteric arteries [58]. Confocal microscopy data
are in agreement with the absence of nNOS effect on sympathetic neurotransmission found in
the tail artery, since a considerably lower amount of this isoform (27% of reduction) was ob-
served in tail arteries, comparatively to mesenteric arteries. Our data also show, for the first
time, that nNOS is distributed in two main locations: one expressed in Schwann cells and an-
other, more abundant in other cells, about 63% and 88% in the adventitia of mesenteric and
tail arteries, respectively. Therefore, it is conceivable that nNOS, expressed in Schwann cells,
might be producing NO that would be causing the inhibition of noradrenaline release from
sympathetic nerves. Our findings are in agreement with this possibility, since the relative
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amount of nNOS expressed in Schwann cells in the two arteries is markedly different: 50% in
mesenteric versus 4% in tail arteries. These data also correlates with the functional results ob-
tained, showing a lack of neuromodulatory role of nNOS in tail arteries whereas in mesenteric
arteries nNOS contributed to reduce noradrenaline release up to 33% (Fig 3).
In summary, the present results suggest that the NOmodulatory role on sympathetic neuro-
transmission differs in the mesenteric and tail arteries depending on the NO source, eNOS
and/or nNOS, involved in its production. Moreover, the signalling cascades induced by the NO
available in each artery are also distinct in the two vessels: in mesenteric artery, NO leads to
adenosine accumulation which activates adenosine A1 receptors causing an inhibition of sym-
pathetic transmission whereas, in tail arteries, this via is not the dominant one, and instead, the
activation of guanylyl cyclase–cGMP- cGMP-dependent protein kinase- voltage-dependent
Ca2+ channels is most likely to occur. Additionally, this work revealed that the location of the
nNOS isoform may also be crucial to the differences in the neuromodulation exerted by NO in
the two arteries studied, since the nNOS isoform present in Schwann cells seem to be the main
source of NO to perivascular sympathetic nerves.
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